Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 12/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.32 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.32 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7736293 | 0.94 | POLB (0.43) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL7726485 | 0.93 | POLB (0.42) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL6932273 | 0.92 | POLB (0.44) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL12404747 | 0.91 | POLB (0.49) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL6365808 | 0.88 | P2RY6 (0.47) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL13151571 | 0.88 | P2RY6 (0.47) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL13672352 | 0.88 | P2RY6 (0.47) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL6362501 | 0.87 | POLB (0.39) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL5525210 | 0.84 | POLB (0.36) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL5531861 | 0.81 | P2RY6 (0.40) | POLBABL1RIN1P2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171048-A1 | Nuclease activity resistance; mixed sequence oligonucleotides containing purine or pyrimidine base in beta anomeric configuration; drug delivery agents; targeting specific DNA and/or RNA sequences | ISIS PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | US | disclosed |
| EP-0942000-B1 | 2'-Modified oligonucleotides | ISIS PHARMACEUTICALS INC (US) | 2004-06-23 | — | — | EP | disclosed |
| US-6476205-B1 | 2′ Modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-6242592-B1 | Process for the preparation of 2′-O-alkyl-guanosine, cytidine, and uridine phosphoramidites | ISIS PHARMACEUTICALS, INC. | 2001-06-05 | — | — | US | disclosed |
| EP-0497875-B1 | 2' MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2000-03-22 | — | — | EP | disclosed |
| EP-0942000-A2 | 2'Modified oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-15 | — | — | EP | disclosed |
| US-5466786-A | Drug delivery | GILEAD SCIENCES (US) | 1995-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171048-A1 | Nuclease activity resistance; mixed sequence oligonucleotides containing purine or pyrimidine base in beta anomeric configuration; drug delivery agents; targeting specific DNA and/or RNA sequences | ADAR, POLM, POLRMT | POLB 9/4885ABL1 4746/4885RIN1 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.